

Hepatitis C Virus (HCV) Bibliography



October 2015

Essential Overview/Background:

1. AASLD, IDSA, IAS-USA. Recommendations for Testing, Managing and Treating Hepatitis C. Available at: <http://www.hcvguidelines.org>
2. WHO Guidelines for the Screening, Care and Treatment of Persons with Hepatitis C Infection. April 2014. Available at: <http://www.who.int/hiv/pub/hepatitis/hepatitis-c-guidelines/en/>
3. European Association for Study of Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. *J Hepatol.* 2014;60:392-420.
4. Action Plan for the Prevention, Care and Treatment of Viral Hepatitis. Updated 2014-2016. Available at: <http://www.cdc.gov/hepatitis/HHS-ActionPlan.htm>
5. Davis G, Alter M, El-Serag H, Poynard T, Jennings L. Aging of Hepatitis C Virus (HCV)-Infected Persons in the United States: A Multiple Cohort Model of HCV Prevalence and Disease Progression. *Gastroenterology.* 2010;138(2):513-521.e6. doi:10.1053/j.gastro.2009.09.067.

HCV in Rhode Island:

1. Special Section on Hepatitis C. *Rhode Island Medical Journal.* 2014; 97(7). ISSN 2327 – 2228.
 - a. Taylor LE. Hepatitis C Virus Infection: From Margin to Center in Rhode Island and Beyond. Available at: <http://rimed.org/rimedicaljournal/2014/07/2014-07-15-hepc-taylor.pdf>
 - b. Taylor LE. Commentary: What price for a cure? Available at: <http://www.rimed.org/rimedicaljournal/2014/07/2014-07-15-hepc-taylor.pdf>
 - c. Kinnard E, Taylor LE, Galárraga O, Marshall B. Estimating the True Prevalence of Hepatitis C Rhode Island. Available at: <http://rimed.org/rimedicaljournal/2014/07/2014-07-19-hepc-kinnard.pdf>
 - d. Alexander-Scott N, Lemire A, Larson E, Bandy U. Prevention and Control of Hepatitis C in Rhode Island. Available at: <http://rimed.org/rimedicaljournal/2014/07/2014-07-25-hepc-alexander-scott.pdf>
 - e. Joseph R, Kofman A, Larney S, Fitzgerald P. Hepatitis C Prevention and Needle Exchange Program in Rhode Island: ENCORE. Available at: <http://rimed.org/rimedicaljournal/2014/07/2014-07-31-hepc-joseph.pdf>

HCV Policy:

1. Aronsohn A, Jensen D. Distributive justice and the arrival of direct-acting antivirals: Who

should be first in line?. *Hepatology*. 2011;53(6):1789-1791. doi:10.1002/hep.24374. Available at: <http://onlinelibrary.wiley.com/doi/10.1002/hep.24374/full>

2. Arora S, Kalishman S, Thornton K et al. Expanding access to hepatitis C virus treatment-Extension for Community Healthcare Outcomes (ECHO) project: Disruptive innovation in specialty care. *Hepatology*. 2010;52(3):1124-1133. doi:10.1002/hep.23802. Available at: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3795614/>
3. Arora S, Thornton K, Murata G et al. Outcomes of Treatment for Hepatitis C Virus Infection by Primary Care Providers. *New England Journal of Medicine*. 2011;364(23):2199-2207. doi:10.1056/nejmoa1009370. Available at: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3820419/>
4. Barua S, Greenwald R, Grebely J, Dore G, Swan T, Taylor L. Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States. *Annals of Internal Medicine*. 2015;163(3):215. doi:10.7326/m15-0406. Available at: <http://annals.org/article.aspx?articleid=2362306>
5. Casalino L. Professionalism and Caring for Medicaid Patients: The 5% Commitment?. *New England Journal of Medicine*. 2013;369(19):1775-1777. doi:10.1056/nejmp1310974.
6. Centers for Disease Control and Prevention. Recommendations for the Identification of Chronic Hepatitis C Virus Infection Among Persons Born During 1945-1965. Morbidity and Mortality Weekly Report. 2012 Aug;61(4). Available at: <http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6104a1.htm>
7. Chhatwal J, Chen Q, Kanwal F. Why We Should Be Willing to Pay for Hepatitis C Treatment. *Clinical Gastroenterology and Hepatology*. 2015;13(10):1711-1713. doi:10.1016/j.cgh.2015.06.005.
8. Chhatwal J, Kanwal F, Roberts M, Dunn M. Cost-Effectiveness and Budget Impact of Hepatitis C Virus Treatment With Sofosbuvir and Ledipasvir in the United States. *Annals of Internal Medicine*. 2015;162(6):397. doi:10.7326/m14-1336.
9. Grebely J, Dore G. What Is Killing People with Hepatitis C Virus Infection?. *Semin Liver Dis*. 2011;31(04):331-339. doi:10.1055/s-0031-1297922.
10. Hepatitis Work Group: Altice R, Charles D, Fishbein D, Gish R, Kim A, Kobayashi RH, Smith C, Striker R, Vuppalanchi R. Improving Patient Access to Hepatitis C Cures: A White Paper From the Hepatitis Therapy Access Physicians Working Group. July 2015. Available at: http://www.ridefeatshepc.com/content/pdfs/Improving_Patient_Access_To_Hepatitis_C_Cures.pdf
11. Kanwal F, El-Serag H. Hepatitis C Virus Treatment: The Unyielding Chasm Between Efficacy and Effectiveness. *Clinical Gastroenterology and Hepatology*. 2014;12(8):1381-1383. doi:10.1016/j.cgh.2014.02.031.
12. Kofman A, Litwin A, Swan T, Pinkston M, Rizzo B, Bryant V, & Taylor L. Short Communication: Heterogeneity in Drug and Alcohol Use-Related Exclusion Criteria in Direct Acting Antiviral Agent Hepatitis C Treatment Trials for Individuals Coinfected with Hepatitis C Virus and HIV. *Clinical Research HIV/AIDS*. 2015;2(2):1019. Available at: <http://www.jscimedcentral.com/HIV-AIDS/HIV-AIDS-2-1019.pdf>

13. Kottlil S, Wright M, Polis M, Masur H. Treatment of Hepatitis C Virus Infection: Is It Time for the Internist to Take the Reins?. *Annals of Internal Medicine*. 2014;161(6):443. doi:10.7326/m14-0741.
14. Leidner A, Chesson H, Xu F, Ward J, Spradling P, Holmberg S. Cost-effectiveness of hepatitis C treatment for patients in early stages of liver disease. *Hepatology*. 2015;61(6):1860-1869. doi:10.1002/hep.27736.
15. Ly K, Xing J, Klevens R, Jiles R, Ward J, Holmberg S. The Increasing Burden of Mortality From Viral Hepatitis in the United States Between 1999 and 2007. *Annals of Internal Medicine*. 2012;156(4):271. doi:10.7326/0003-4819-156-4-201202210-00004.
16. Najafzadeh M, Andersson K, Shrank W et al. Cost-Effectiveness of Novel Regimens for the Treatment of Hepatitis C Virus. *Annals of Internal Medicine*. 2015;162(6):407. doi:10.7326/m14-1152. Available at: <http://nvhr.org/sites/default/files/.users/u27/HCV%20Cost%20effective%20Najafzadeh%20Annals%202015.pdf>
17. Reau N, Jensen D. Sticker shock and the price of new therapies for hepatitis C: Is it worth it?. *Hepatology*. 2014;59(4):1246-1249. doi:10.1002/hep.27039. Available at: <http://onlinelibrary.wiley.com/doi/10.1002/hep.27039/full>
18. Rein D, Wittenborn J, Smith B, Liffmann D, Ward J. The Cost-effectiveness, Health Benefits, and Financial Costs of New Antiviral Treatments for Hepatitis C Virus. *Clin Infect Dis*. 2015;61(2):157-168. doi:10.1093/cid/civ220. Available at: http://nvhr.org/sites/default/files/.users/u27/Clin%20Infect%20Dis.-2015-Rein-cid_civ220%281%29.pdf
19. Saag M. Editorial Commentary: Getting Smart in How We Pay for HCV Drugs: KAOS vs CONTROL. *Clin Infect Dis*. 2015;61(2):169-170. doi:10.1093/cid/civ221. Available at: http://nvhr.org/sites/default/files/.users/u27/Clin%20Infect%20Dis.-2015-Saag-cid_civ221.pdf
20. Tsochatzis E, Crossan C, Longworth L et al. Cost-effectiveness of noninvasive liver fibrosis tests for treatment decisions in patients with chronic hepatitis C. *Hepatology*. 2014;60(3):832-843. doi:10.1002/hep.27296.
21. Volk M, Tocco R, Saini S, Lok A. Public health impact of antiviral therapy for hepatitis C in the United States. *Hepatology*. 2009;50(6):1750-1755. doi:10.1002/hep.23220. Available at: <http://onlinelibrary.wiley.com/doi/10.1002/hep.23220/full>
22. Wong J, McQuillan G, McHutchison, Poynard T. Estimating Future Hepatitis C Morbidity, Mortality, and Costs in the United States. *Am J Public Health*. 2000;90(10):1562-1569. doi:10.2105/ajph.90.10.1562. Available at: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1446368/pdf/11029989.pdf>

HCV Screening:

1. Boschert S. Best HCV value? Screen All Baby Boomers, Treat All. *Internal Medicine News*. 2014 Dec:19-21. Available at:

<http://www.pm360online.com/best-hcv-value-screen-all-baby-boomers-treat-all-infections/>

2. Coffin P, Reynolds A. Ending hepatitis C in the United States: the role of screening. *Hepatic Medicine: Evidence and Research*. 2014;79. doi:10.2147/hmer.s40940. Available at: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4086667/>
3. Coffin P, Scott J, Golden M, Sullivan S. Cost-effectiveness and Population Outcomes of General Population Screening for Hepatitis C. *Clinical Infectious Diseases*. 2012;54(9):1259-1271. doi:10.1093/cid/cis011. Available at: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3404694/>
4. Koretz R, Lin K, Ioannidis J, Lenzer J. Is widespread screening for hepatitis C justified?. *BMJ*. 2015;350:g7809-g7809. doi:10.1136/bmj.g7809. Available at: <http://www.pm360online.com/best-hcv-value-screen-all-baby-boomers-treat-all-infections/>
5. Lushniak B. Surgeon General's Perspectives. *Public Health Reports*. 2014;129(3):220. Available at: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3982548/>.
6. Moyer V. Screening for Hepatitis C Virus Infection in Adults: U.S. Preventive Services Task Force Recommendation Statement. *Annals of Internal Medicine*. 2013;159(5):349. doi:10.7326/0003-4819-159-5-201309030-00672.
7. Ngo-Metzger Q, Ward J, Valdiserri R. Expanded Hepatitis C Virus Screening Recommendations Promote Opportunities for Care and Cure. *Annals of Internal Medicine*. 2013;159(5):364. doi:10.7326/0003-4819-159-5-201309030-00675. Available at: <http://annals.org/article.aspx?articleid=1700384>
8. Smith B, Yartel A, Krauskopf K et al. Hepatitis C Virus Antibody Positivity and Predictors Among Previously Undiagnosed Adult Primary Care Outpatients: Cross-Sectional Analysis of a Multisite Retrospective Cohort Study. *Clinical Infectious Diseases*. 2015;60(8):1145-1152. doi:10.1093/cid/civ002. Available at: <http://cid.oxfordjournals.org/content/60/8/1145.long>
9. Taylor L, Foont J, DeLong A et al. The Spectrum of Undiagnosed Hepatitis C Virus Infection in a US HIV Clinic. *AIDS Patient Care and STDs*. 2014;28(1):4-9. doi:10.1089/apc.2013.0130. Available at: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3894677/>

HCV and People who Inject Drugs (PWID):

1. Arain A. Eligibility of persons who inject drugs for treatment of hepatitis C virus infection. *World Journal of Gastroenterology*. 2014;20(36):12722. doi:10.3748/wjg.v20.i36.12722.
2. Dore G, Hellard M, Matthews G et al. Effective Treatment of Injecting Drug Users With Recently Acquired Hepatitis C Virus Infection. *Gastroenterology*. 2010;138(1):123-135.e2. doi:10.1053/j.gastro.2009.09.019. Available at: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2813391/>
3. Edlin B, Seal K, Lorvick J et al. Is It Justifiable to Withhold Treatment for Hepatitis C from Illicit-Drug Users? *New England Journal of Medicine*. 2001;345(3):211-214.

doi:10.1056/nejm200107193450311. Available at:
<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1510901/>

4. Edlin B, Winkelstein E. Can hepatitis C be eradicated in the United States?. *Antiviral Research*. 2014;110:79-93. doi:10.1016/j.antiviral.2014.07.015.
5. Edlin B, Winkelstein E. Unanswered Questions: A Research Agenda for Hepatitis C Eradication. Supplement to can hepatitis C be eradicated in the United States? *Antiviral Res*. 2014 Oct 7;110.
6. Garfein R, Golub E, Greenberg A et al. A peer-education intervention to reduce injection risk behaviors for HIV and hepatitis C virus infection in young injection drug users. *AIDS*. 2007;21(14):1923-1932. doi:10.1097/qad.0b013e32823f9066.
7. Grebely J, Dore G. Can hepatitis C virus infection be eradicated in people who inject drugs?. *Antiviral Research*. 2014;104:62-72. doi:10.1016/j.antiviral.2014.01.002.
8. Grebely J, Genoway K, Khara M et al. Treatment uptake and outcomes among current and former injection drug users receiving directly observed therapy within a multidisciplinary group model for the treatment of hepatitis C virus infection. *International Journal of Drug Policy*. 2007;18(5):437-443. doi:10.1016/j.drugpo.2007.01.009.
9. Grebely J, Haire B, Taylor L et al. Excluding people who use drugs or alcohol from access to hepatitis C treatments - Is this fair, given the available data?. *Journal of Hepatology*. 2015;63(4):779-782. doi:10.1016/j.jhep.2015.06.014.
10. Grebely J, Oser M, Taylor L, Dore G. Breaking Down the Barriers to Hepatitis C Virus (HCV) Treatment Among Individuals With HCV/HIV Coinfection: Action Required at the System, Provider, and Patient Levels. *Journal of Infectious Diseases*. 2013;207(suppl 1):S19-S25. doi:10.1093/infdis/jis928. Available at:
http://jid.oxfordjournals.org/content/207/suppl_1/S19.full
11. Grebely J, Robaey G, Bruggmann P et al. Recommendations for the management of hepatitis C virus infection among people who inject drugs. *International Journal of Drug Policy*. 2015;26(10):1028-1038. doi:10.1016/j.drugpo.2015.07.005.
12. Harris K, Arnsten J, Litwin A. Successful Integration of Hepatitis C Evaluation and Treatment Services With Methadone Maintenance. *Journal of Addiction Medicine*. 2010;4(1):20-26. doi:10.1097/adm.0b013e3181add3de. Available at:
<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2872238/>
13. Hellard M, Sacks-Davis R, Gold J. Hepatitis C Treatment for Injection Drug Users: A Review of the Available Evidence. *Clinical Infectious Diseases*. 2009;49(4):561-573. doi:10.1086/600304. Available at: <http://cid.oxfordjournals.org/content/49/4/561.long>
14. Higgs P, Sacks-Davis R, Gold J, Hellard M. Barriers to receiving hepatitis C treatment for people who inject drugs: Myths and evidence. *Hepatitis Monthly*. 2011;11(7):513. Available at: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3212767/>
15. Jargens R, Csete J, Amon J, Baral S, Beyrer C. People who use drugs, HIV, and human rights. *The Lancet*. 2010;376(9739):475-485. doi:10.1016/s0140-6736(10)60830-6.
16. Litwin A, Harris K, Nahvi S et al. Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment

program. *Journal of Substance Abuse Treatment*. 2009;37(1):32-40.
doi:10.1016/j.jsat.2008.09.009. Available at:
<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2692471/>

17. Litwin A, Soloway I, Gourevitch M. Integrating Services for Injection Drug Users Infected with Hepatitis C Virus with Methadone Maintenance Treatment: Challenges and Opportunities. *Clinical Infectious Diseases*. 2005;40(s5):S339-S345. doi:10.1086/427450. Available at: http://cid.oxfordjournals.org/content/40/Supplement_5/S339.long
18. Martin N, Vickerman P, Grebely J et al. Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. *Hepatology*. 2013;58(5):1598-1609. doi:10.1002/hep.26431. Available at: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3933734/>
19. Martin N, Vickerman P, Miners A et al. Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations. *Hepatology*. 2011;55(1):49-57. doi:10.1002/hep.24656. Available at: <http://onlinelibrary.wiley.com/doi/10.1002/hep.24656/full>
20. Masson C, Delucchi K, McKnight C et al. A Randomized Trial of a Hepatitis Care Coordination Model in Methadone Maintenance Treatment. *Am J Public Health*. 2013;103(10):e81-e88. doi:10.2105/ajph.2013.301458. Available at: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3853128/>
21. Schaefer M, Heinz A, Backmund M. Treatment of chronic hepatitis C in patients with drug dependence: time to change the rules?. *Addiction*. 2004;99(9):1167-1175. doi:10.1111/j.1360-0443.2004.00821.x.
22. Sylvestre D, Litwin A, Clements B, Gourevitch M. The impact of barriers to hepatitis C virus treatment in recovering heroin users maintained on methadone. *Journal of Substance Abuse Treatment*. 2005;29(3):159-165. doi:10.1016/j.jsat.2005.06.002.
23. Sylvestre D, Zweben J. Integrating HCV services for drug users: A model to improve engagement and outcomes. *International Journal of Drug Policy*. 2007;18(5):406-410. doi:10.1016/j.drugpo.2007.01.010.
24. Taylor L, Bowman S, Chapman S et al. Treatment for hepatitis C virus genotype 1 infection in HIV-infected individuals on methadone maintenance therapy. *Drug and Alcohol Dependence*. 2011;116(1-3):233-237. doi:10.1016/j.drugalcdep.2010.11.016. Available at: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4212315/>
25. Treloar C, Rance J, Dore G, Grebely J. Barriers and facilitators for assessment and treatment of hepatitis C virus infection in the opioid substitution treatment setting: insights from the ETHOS study. *Journal of Viral Hepatitis*. 2013;21(8):560-567. doi:10.1111/jvh.12183.
26. *Clinical Infectious Diseases*. 2013;57(Suppl. 2). Full supplement available at: http://cid.oxfordjournals.org/content/57/suppl_2.toc
 - a. Grebely J, Bruggmann P, Backmund M, Dore G. Moving the Agenda Forward: The Prevention and Management of Hepatitis C Virus Infection Among People Who Inject Drugs. *Clinical Infectious Diseases*. 2013;57(suppl 2):S29-S31. doi:10.1093/cid/cit264.

- b. Page K, Morris M, Hahn J, Maher L, Prins M. Injection Drug Use and Hepatitis C Virus Infection in Young Adult Injectors: Using Evidence to Inform Comprehensive Prevention. *Clinical Infectious Diseases*. 2013;57(suppl 2):S32-S38. doi:10.1093/cid/cit300.
- c. Martin N, Hickman M, Hutchinson S, Goldberg D, Vickerman P. Combination Interventions to Prevent HCV Transmission Among People Who Inject Drugs: Modeling the Impact of Antiviral Treatment, Needle and Syringe Programs, and Opiate Substitution Therapy. *Clinical Infectious Diseases*. 2013;57(suppl 2):S39-S45. doi:10.1093/cid/cit296.
- d. Cox A, Thomas D. Hepatitis C Virus Vaccines Among People Who Inject Drugs. *Clinical Infectious Diseases*. 2013;57(suppl 2):S46-S50. doi:10.1093/cid/cit329.
- e. Treloar C, Rance J, Backmund M. Understanding Barriers to Hepatitis C Virus Care and Stigmatization From a Social Perspective. *Clinical Infectious Diseases*. 2013;57(suppl 2):S51-S55. doi:10.1093/cid/cit263.
- f. Bruggmann P, Litwin A. Models of Care for the Management of Hepatitis C Virus Among People Who Inject Drugs: One Size Does Not Fit All. *Clinical Infectious Diseases*. 2013;57(suppl 2):S56-S61. doi:10.1093/cid/cit271.
- g. Alavi M, Grebely J, Micallef M et al. Assessment and Treatment of Hepatitis C Virus Infection Among People Who Inject Drugs in the Opioid Substitution Setting: ETHOS Study. *Clinical Infectious Diseases*. 2013;57(suppl 2):S62-S69. doi:10.1093/cid/cit305.
- h. Post J, Arain A, Lloyd A. Enhancing Assessment and Treatment of Hepatitis C in the Custodial Setting. *Clinical Infectious Diseases*. 2013;57(suppl 2):S70-S74. doi:10.1093/cid/cit265.
- i. Crawford S, Bath N. Peer Support Models for People With a History of Injecting Drug Use Undertaking Assessment and Treatment for Hepatitis C Virus Infection. *Clinical Infectious Diseases*. 2013;57(suppl 2):S75-S79. doi:10.1093/cid/cit297.
- j. Aspinall E, Corson S, Doyle J et al. Treatment of Hepatitis C Virus Infection Among People Who Are Actively Injecting Drugs: A Systematic Review and Meta-analysis. *Clinical Infectious Diseases*. 2013;57(suppl 2):S80-S89. doi:10.1093/cid/cit306.
- k. Hilsden R, Macphail G, Grebely J, Conway B, Lee S. Directly Observed Pegylated Interferon Plus Self-Administered Ribavirin for the Treatment of Hepatitis C Virus Infection in People Actively Using Drugs: A Randomized Controlled Trial. *Clinical Infectious Diseases*. 2013;57(suppl 2):S90-S96. doi:10.1093/cid/cit327.
- l. Reimer J, Schmidt C, Schulte B et al. Psychoeducation Improves Hepatitis C Virus Treatment During Opioid Substitution Therapy: A Controlled, Prospective Multicenter Trial. *Clinical Infectious Diseases*. 2013;57(suppl 2):S97-S104. doi:10.1093/cid/cit307.
- m. Grady B, Schinkel J, Thomas X, Dalgard O. Hepatitis C Virus Reinfection Following Treatment Among People Who Use Drugs. *Clinical Infectious Diseases*. 2013;57(suppl 2):S105-S110. doi:10.1093/cid/cit301.

- n. Schaefer M, Sarkar R, Diez-Quevedo C. Management of Mental Health Problems Prior to and During Treatment of Hepatitis C Virus Infection in Patients With Drug Addiction. *Clinical Infectious Diseases*. 2013;57(suppl 2):S111-S117. doi:10.1093/cid/cit266.
- o. Taylor L, Swan T, Matthews G. Management of Hepatitis C Virus/HIV Coinfection Among People Who Use Drugs in the Era of Direct-Acting Antiviral-Based Therapy. *Clinical Infectious Diseases*. 2013;57(suppl 2):S118-S124. doi:10.1093/cid/cit326.
- p. Mauss S, Klinker H. Drug-Drug Interactions in the Treatment of HCV Among People Who Inject Drugs. *Clinical Infectious Diseases*. 2013;57(suppl 2):S125-S128. doi:10.1093/cid/cit299.
- q. Robaey G, Grebely J, Mauss S et al. Recommendations for the Management of Hepatitis C Virus Infection Among People Who Inject Drugs. *Clinical Infectious Diseases*. 2013;57(suppl 2):S129-S137. doi:10.1093/cid/cit302.

HCV and Alcohol Use:

1. Anand B, Currie S, Dieperink E et al. Alcohol Use and Treatment of Hepatitis C Virus: Results of a National Multicenter Study. *Gastroenterology*. 2006;130(6):1607-1616. doi:10.1053/j.gastro.2006.02.023.
2. Bruggmann P, Dampz M, Gerlach T, Kravec L, Falcato L. Treatment outcome in relation to alcohol consumption during hepatitis C therapy: An analysis of the Swiss Hepatitis C Cohort Study. *Drug and Alcohol Dependence*. 2010;110(1-2):167-171. doi:10.1016/j.drugalcdep.2010.02.016.
3. Corrao G, Arico S. Independent and combined action of hepatitis C virus infection and alcohol consumption on the risk of symptomatic liver cirrhosis. *European Journal of Gastroenterology & Hepatology*. 1998;10(9):815. doi:10.1097/00042737-199809000-00019.
4. Hutchinson S, Bird S, Goldberg D. Influence of Alcohol on the Progression of Hepatitis C Virus Infection: A Meta-analysis. *Clinical Gastroenterology and Hepatology*. 2005;3(11):1150-1159. doi:10.1016/s1542-3565(05)00407-6. Available at: <http://onlinelibrary.wiley.com/doi/10.1002/hep.510270404/epdf>
5. Le Lan C, Guillygomarc'h A, Danielou H et al. A multi-disciplinary approach to treating hepatitis C with interferon and ribavirin in alcohol-dependent patients with ongoing abuse. *Journal of Hepatology*. 2012;56(2):334-340. doi:10.1016/j.jhep.2011.05.021.
6. Rosman A, Waraich A, Galvin K, Casiano J, Paronetto F, Lieber C. Alcoholism is Associated with Hepatitis C but not Hepatitis B in an Urban Population. *American Journal of Gastroenterology*. Mar 1996;91(3):498-505.
7. Singal A, Anand B. Mechanisms of Synergy Between Alcohol and Hepatitis C Virus. *Journal of Clinical Gastroenterology*. 2007;41(8):761-772. doi:10.1097/mcg.0b013e3180381584.

HCV/HIV Coinfection:

1. Freiman J, Huang W, White L et al. Current Practices of Screening for Incident Hepatitis C Virus (HCV) Infection Among HIV-Infected, HCV-Uninfected Individuals in Primary Care. *Clinical Infectious Diseases*. 2014;59(12):1686-1693. doi:10.1093/cid/ciu698.
2. Garg S, Taylor L, Grasso C, Mayer K. Prevalent and Incident Hepatitis C Virus Infection Among HIV-Infected Men Who Have Sex With Men Engaged in Primary Care in a Boston Community Health Center. *Clinical Infectious Diseases*. 2013;56(10):1480-1487. doi:10.1093/cid/cit054. Available at: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3634307/>
3. Graham C. Hepatitis C and HIV Co-infection. *JAMA*. 2015;313(12):1217. doi:10.1001/jama.2015.1111.
4. Taylor L, Holubar M, Wu K et al. Incident Hepatitis C Virus Infection among US HIV-Infected Men Enrolled in Clinical Trials. *Clinical Infectious Diseases*. 2011;52(6):812-818. doi:10.1093/cid/ciq201. Available at: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3106260/>
5. Taylor L, Swan T, Matthews G. Management of Hepatitis C Virus/HIV Coinfection Among People Who Use Drugs in the Era of Direct-Acting Antiviral-Based Therapy. *Clinical Infectious Diseases*. 2013;57(suppl 2):S118-S124. doi:10.1093/cid/cit326. Available at: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3722078/>
6. Taylor L, Swan T, Mayer K. HIV Coinfection With Hepatitis C Virus: Evolving Epidemiology and Treatment Paradigms. *Clinical Infectious Diseases*. 2012;55(suppl 1):S33-S42. doi:10.1093/cid/cis367. Available at: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491862/>
7. Taylor, L. HIV/Viral Hepatitis Coinfection: The Immunology Center Experience. *Medicine & Health Rhode Island*. 2009;92(7):234-236. Available at: <http://www.rimed.org/medhealthri/2009-07/2009-07-234.pdf>
8. U.S. Department of Health and Human Services Health Resources and Services Administration HIV/AIDS Bureau, Special Projects of National Significance Program. Training and Implementing Guide: Delivering Hepatitis C Treatment in an HIV Care Setting. 2014 Sep. Available at: https://careacttarget.org/sites/default/files/file-upload/resources/HepC_v7.pdf
9. U.S. Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents- A Working Group of the Office of AIDS Research Advisory Council (OARAC). Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents: Considerations for Antiretroviral Use in Patients with Coinfections. 2014 Nov. Available at: <https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf>

Evaluating Fibrosis:

1. Berenguer J, Zamora F, Aldamiz-Echevarria T et al. Comparison of the Prognostic Value

of Liver Biopsy and FIB-4 Index in Patients Coinfected With HIV and Hepatitis C Virus. *Clinical Infectious Diseases*. 2014;60(6):950-958. doi:10.1093/cid/ciu939.

2. Holmberg S, Lu M, Rupp L et al. Noninvasive Serum Fibrosis Markers for Screening and Staging Chronic Hepatitis C Virus Patients in a Large US Cohort. *Clinical Infectious Diseases*. 2013;57(2):240-246. doi:10.1093/cid/cit245.
3. Smith D, Combellick J, Jordan A, Hagan H. Hepatitis C virus (HCV) disease progression in people who inject drugs (PWID): A systematic review and meta-analysis. *International Journal of Drug Policy*. 2015;26(10):911-921. doi:10.1016/j.drugpo.2015.07.004.

Cirrhosis:

1. Yadav A, Vargas H. Care of the patient with cirrhosis. *Clinical Liver Disease*. 2015;5(4):100-104. doi:10.1002/cld.462.

Vetted Websites:

- <http://www.cdc.gov/hepatitis/HCV/index.htm>
- <http://www.treatmentactiongroup.org/hcv>
- <http://www.natap.org/>
- <http://hcvadvocate.org/>
- <http://www.oasiscliniconline.org/>
- <http://www.hivandhepatitis.com/>
- <http://nvhr.org/>
- <http://www.hepeducation.org/>